Literature DB >> 15149315

EGF-related growth factors in the pathogenesis of murine ARPKD.

Katherine MacRae Dell1, Raghad Nemo, William E Sweeney, Ellis D Avner.   

Abstract

BACKGROUND: Epidermal growth factor (EGF), transforming growth factor-alpha (TGF-alpha) and their receptor, EGFR, play key roles in polycystic kidney disease (PKD) pathogenesis. Renal expression of two related growth factors, amphiregulin and heparin-binding EGF, has not been examined previously in PKD. The aims of this study of murine autosomal-recessive polycystic kidney disease (ARPKD) were (1) to characterize amphiregulin and heparin-binding EGF expression in cystic versus normal kidneys and cells; and (2) to identify the functional effects of abnormal EGF-related growth factor expression.
METHODS: Amphiregulin and heparin-binding-EGF expression were examined by immunohistology and Western blot of kidneys and conditionally-immortalized collecting tubule cells obtained from cystic bpk mice (a murine model of ARPKD) and normal littermates. EGF, TGF-alpha, amphiregulin, and heparin-binding EGF in vitro effects on cystic and control collecting tubule cells were assessed by cell proliferation, cyst fluid mitogenicity, and EGFR activation.
RESULTS: By immunohistology, amphiregulin and heparin-binding EGF localized to apical and basolateral surfaces of proximal tubule cysts > normal proximal tubules. In cystic collecting tubules, heparin-binding EGF (but not amphiregulin) localized to both apical and basolateral surfaces; whereas in normal collecting tubules, amphiregulin and heparin-binding EGF localized to the basolateral surface only. Increased amphiregulin and heparin-binding EGF expression by Western blot was seen in cystic vs. normal kidneys and increased heparin-binding EGF (but not amphiregulin) expression was present in cystic collecting tubule cell lines vs. controls. EGF, TGF-alpha, amphiregulin, and heparin-binding EGF were all mitogenic to cystic > control collecting tubule cells. Immunoprecipitation of EGF and TGF-alpha reduced cyst fluid mitogenicity by almost 80%, whereas heparin-binding EGF and amphiregulin immunoprecipitations had minimal effects. Differential receptor activation was also seen: Heparin-binding EGF markedly activated EGFR (>EGF = TGF-alpha > amphiregulin), with a greater effect seen in cystic vs. control collecting tubule cells.
CONCLUSION: Multiple EGF-related growth factors are abnormally expressed in murine ARPKD and may have differential roles in disease pathogenesis. In particular, newly identified abnormalities in heparin-binding EGF expression in cystic kidneys and cells may have important implications for disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15149315     DOI: 10.1111/j.1523-1755.2004.00623.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  29 in total

1.  Role of genetic modifiers in an orthologous rat model of ARPKD.

Authors:  Caitlin C O'Meara; Matthew Hoffman; William E Sweeney; Shirng-Wern Tsaih; Bing Xiao; Howard J Jacob; Ellis D Avner; Carol Moreno
Journal:  Physiol Genomics       Date:  2012-06-05       Impact factor: 3.107

2.  Autosomal recessive polycystic kidney disease and congenital hepatic fibrosis: summary statement of a first National Institutes of Health/Office of Rare Diseases conference.

Authors:  Meral Gunay-Aygun; Ellis D Avner; Robert L Bacallao; Peter L Choyke; Joseph T Flynn; Gregory G Germino; Lisa Guay-Woodford; Peter Harris; Theo Heller; Julie Ingelfinger; Frederick Kaskel; Robert Kleta; Nicholas F LaRusso; Parvathi Mohan; Gregory J Pazour; Benjamin L Shneider; Vicente E Torres; Patricia Wilson; Colleen Zak; Jing Zhou; William A Gahl
Journal:  J Pediatr       Date:  2006-08       Impact factor: 4.406

3.  The Lipocalin LPR-1 Cooperates with LIN-3/EGF Signaling To Maintain Narrow Tube Integrity in Caenorhabditis elegans.

Authors:  Pu Pu; Craig E Stone; Joshua T Burdick; John I Murray; Meera V Sundaram
Journal:  Genetics       Date:  2016-12-30       Impact factor: 4.562

4.  Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy.

Authors:  Jan M Williams; Jin Zhang; Paula North; Steven Lacy; Michael Yakes; Annette Dahly-Vernon; Richard J Roman
Journal:  Am J Physiol Renal Physiol       Date:  2011-01-12

5.  Transforming growth factor alpha (TGF-alpha) and other targets of tumor necrosis factor-alpha converting enzyme (TACE) in murine polycystic kidney disease.

Authors:  Raghad Nemo; Noel Murcia; Katherine Macrae Dell
Journal:  Pediatr Res       Date:  2005-03-17       Impact factor: 3.756

6.  EGF Receptor Inhibition by Erlotinib Increases Aquaporin 2-Mediated Renal Water Reabsorption.

Authors:  Pui W Cheung; Naohiro Nomura; Anil V Nair; Nutthapoom Pathomthongtaweechai; Lars Ueberdiek; Hua A Jenny Lu; Dennis Brown; Richard Bouley
Journal:  J Am Soc Nephrol       Date:  2016-03-09       Impact factor: 10.121

7.  Parathyroid hormone-related protein promotes epithelial-mesenchymal transition.

Authors:  Juan Antonio Ardura; Sandra Rayego-Mateos; David Rámila; Marta Ruiz-Ortega; Pedro Esbrit
Journal:  J Am Soc Nephrol       Date:  2009-12-03       Impact factor: 10.121

Review 8.  The role of the EGF family of ligands and receptors in renal development, physiology and pathophysiology.

Authors:  Fenghua Zeng; Amar B Singh; Raymond C Harris
Journal:  Exp Cell Res       Date:  2008-08-19       Impact factor: 3.905

9.  Epidermal growth factor-induced proliferation of collecting duct cells from Oak Ridge polycystic kidney mice involves activation of Na+/H+ exchanger.

Authors:  Sonya D Coaxum; Mary G Blanton; Alisha Joyner; Tanjina Akter; P Darwin Bell; Louis M Luttrell; John R Raymond; Mi-Hye Lee; Paul A Blichmann; Maria N Garnovskaya; Takamitsu Saigusa
Journal:  Am J Physiol Cell Physiol       Date:  2014-07-23       Impact factor: 4.249

10.  20-HETE mediates proliferation of renal epithelial cells in polycystic kidney disease.

Authors:  Frank Park; William E Sweeney; Guangfu Jia; Richard J Roman; Ellis D Avner
Journal:  J Am Soc Nephrol       Date:  2008-07-02       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.